455 related articles for article (PubMed ID: 15370100)
1. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
Ito H; Miyakoda G; Mori T
Platelets; 2004 Aug; 15(5):293-301. PubMed ID: 15370100
[TBL] [Abstract][Full Text] [Related]
2. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
3. P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist.
Zhao L; Bath PM; May J; Lösche W; Heptinstall S
Platelets; 2003; 14(7-8):473-80. PubMed ID: 14713516
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro.
Inoue T; Sohma R; Morooka S
Thromb Res; 1999 Feb; 93(3):137-43. PubMed ID: 10030830
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
Matsumoto Y; Marukawa K; Okumura H; Adachi T; Tani T; Kimura Y
Thromb Res; 1999 Jul; 95(1):19-29. PubMed ID: 10403683
[TBL] [Abstract][Full Text] [Related]
6. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
8. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
Straub A; Wendel HP; Azevedo R; Ziemer G
Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
[TBL] [Abstract][Full Text] [Related]
9. Platelet GPIIb/IIIa is activated and platelet-leukocyte coaggregates formed in vivo during hemodialysis.
Kawabata K; Nakai S; Miwa M; Sugiura T; Otsuka Y; Shinzato T; Hiki Y; Tomimatsu I; Ushida Y; Hosono F; Maeda K
Nephron; 2002 Apr; 90(4):391-400. PubMed ID: 11961397
[TBL] [Abstract][Full Text] [Related]
10. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.
Caron A; Théorêt JF; Mousa SA; Merhi Y
J Cardiovasc Pharmacol; 2002 Aug; 40(2):296-306. PubMed ID: 12131559
[TBL] [Abstract][Full Text] [Related]
11. Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets.
McKenzie ME; Malinin AI; Bell CR; Dzhanashvili A; Horowitz ED; Oshrine BR; Atar D; Serebruany VL
Blood Coagul Fibrinolysis; 2003 Apr; 14(3):249-53. PubMed ID: 12695747
[TBL] [Abstract][Full Text] [Related]
12. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro.
Scholz T; Zhao L; Temmler U; Bath P; Heptinstall S; Lösche W
Platelets; 2002 Nov; 13(7):401-6. PubMed ID: 12487787
[TBL] [Abstract][Full Text] [Related]
13. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
Inoue T; Uchida T; Sakuma M; Imoto Y; Ozeki Y; Ozaki Y; Hikichi Y; Node K
J Am Coll Cardiol; 2004 Oct; 44(7):1408-14. PubMed ID: 15464320
[TBL] [Abstract][Full Text] [Related]
14. The involvement of adhesion molecules and lipid mediators in the adhesion of human platelets to eosinophils.
Jawień J; Lomnicka M; Korbut R; Chłopicki S
J Physiol Pharmacol; 2005 Dec; 56(4):637-48. PubMed ID: 16391420
[TBL] [Abstract][Full Text] [Related]
15. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms underlying the inhibitory effects of lipopolysaccharide on human platelet adhesion.
Morganti RP; Cardoso MH; Pereira FG; Lorand-Metze I; De Nucci G; Marcondes S; Antunes E
Platelets; 2010; 21(4):260-9. PubMed ID: 20218907
[TBL] [Abstract][Full Text] [Related]
17. Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients.
Chandler AB; Earhart AD; Speich HE; Kueter TJ; Hansen J; White MM; Jennings LK
Thromb Res; 2010 Jan; 125(1):44-52. PubMed ID: 19487018
[TBL] [Abstract][Full Text] [Related]
18. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.
Straub A; Schiebold D; Wendel HP; Azevedo R; Dietz K; Ziemer G
Thromb Res; 2008; 122(3):383-9. PubMed ID: 18304613
[TBL] [Abstract][Full Text] [Related]
19. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion.
Kupatt C; Wichels R; Horstkotte J; Krombach F; Habazettl H; Boekstegers P
J Leukoc Biol; 2002 Sep; 72(3):455-61. PubMed ID: 12223512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
